NL-OMON35496已完成3 期
ACNS 0331: a study evaluating limited target volume boost irradiation and reduced dose craniospinal radiotherapy (18.00 Gy) and chemotherapy in children with newly diagnosed standard risk medulloblastoma: a phase III double randomized trial. - ACNS 0331 Medulloblastoma SR
Stichting Kinderoncologie Nederland0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •1) maximal cross-sectional area of residual tumor of 1.5 cm2 or less
- •2) no evidence of metastatic disease in the head, spine or CSF
- •3) performance level >/ 50% (Karnofsky/Lansky)
- •4)no previous radiotherapy or chemotherapy other than corticosteroids
- •5) adequate renal function
- •6) adequate liver function
- •7) adequate bone marrow function
- •8) no pregnancy/breast feeding
- •9) signed informed consent
- •10) national and institutional requirements for human studies must be met
排除标准
- •1) maximal cross-sectional area of residual tumor larger than 1.5 cm2
- •2) evidence of metastatic disease in the head, spine or CSF
- •3) performance level below 50% (Karnofsky/Lansky)
- •4) previous radiotherapy or chemotherapy
- •5) inadequate renal function
- •6) inadequate liver function
- •7) inadequate bone marrow function
- •8) pregnancy/breast feeding
- •9) no signed informed consent
- •10) national and institutional requirements for human studies are not met
研究者
相似试验
进行中（未招募）
不适用
ACNS0331A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial.An Intergroup Study for Participation by COG and the Dutch Childhood Oncology Group – SKION (Stichting Kinderoncologie Nederland) - ACNS0331Medulloblastoom standard riskMedDRA version: 12.0Level: LLTClassification code 10027107Term: MedulloblastomaMedDRA version: 12.0Level: PTClassification code 10027107Term: MedulloblastomaEUCTR2009-010004-28-NLCOG455
招募中
1 期
Protocol Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C=1%)hemophilia AMedDRA version: 20.0Level: LLTClassification code: 10060613Term: Hemophilia A (Factor VIII) Class: 10010331CTIS2024-512075-12-00Pfizer Inc.75
招募中
1 期
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)severe to moderately severe hemophilia B (FIX:C = 2%)MedDRA version: 20.0Level: LLTClassification code: 10060614Term: Hemophilia B (Factor IX) Class: 10010331CTIS2022-502844-11-00Pfizer Inc.56
已完成
不适用
Cross over study to assess the effect of AM-301 on allergic symptoms during allergen challenge in the Fraunhofer Allergen Challenge Chamber (ACC) in comparison to hydroxypropylmethylcellulose powderJ30.1Allergic rhinitis due to pollenDRKS00024356Altamira Medica AG36
进行中（未招募）
不适用
Study to evaluate the efficay, safety and local tolerability of triptorelin pamoate (11,25mg) injected sub cuteanously in patients with (locally advanced or metastatic) prostate cancer.EUCTR2012-001279-35-PLIpsen Pharma S.A.S120